Low-dose Mifepristone (25 mg) in Treatment of Uterine Myoma in Perimenopausal Women

Objectives To evaluate the effect of low-dose mifepristone (25 mg) on symptomatic myoma in perimenoapausal women. Study design Prospective observational clinical trial. Materials and methods Ninety-three perimenopausal women of age 35 to 50 years having symptomatic myoma were selected from gynecology outpatient department and given 25 mg mifepristone once daily continuously for 3 months. Baseline uterine size, uterine volume, myoma size, volume, their number, position, characteristics, hemoglobin and blood parameters, were taken and followed monthly for 6 months. Bleeding and pain scores were checked on monthly visits. Change in above parameters were tabulated during the first 3 months treatment phase and then next 3 months post-treatment phase for analysis. Statistical analysis Done by calculating mean, standard deviation, standard error and percentage distribution of variables. Results Menorrhagia was the commonest symptom which led patients to report to hospital. Mean uterine volume reduced to 63.69% of baseline, mean dominant myoma volume reduced to 53.62% and hemoglobin level raised to 137% after complete treatment of 3 months. Changes persisted in next 3 months post-treatment follow-up, while hysterectomy was required in 10 (12.2%) cases. Conclusion Three months treatment of 25 mg mifepristone effectively controls bleeding, reduces the uterine and myoma volume and thus can avoid blood transfusion and hysterectomy in a lot of symptomatic myoma cases. How to cite this article Seth S, Singh E, Mathur AS, Gupta G, Nagrath A. Low-dose Mifepristone (25 mg) in Treatment of Uterine Myoma in Perimenopausal Women. J South Asian Feder Menopause Soc 2013;1(1):34-37.